Phase 2 N=30 Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · CLL
Primary: Overall Response Rate (ORR) — 25 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014
Phase 2 N=15 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia
Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…
Phase 2 N=45 Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Leukemia
Primary: Percentage of Patients Achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) on Single Agent CC-5013 at 6 Months — 68.9 percentage of…
Phase 2 N=22 Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Complete Response Rate — 36 percentage of patients
Phase 2 N=80 Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Number of Participants With an Overall Response — 23; 3; 26 Participants
Phase 2 N=12 Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…
Phase 2 N=9 Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy
Chronic Lymphocytic Leukemia
Primary: Maximum Tolerated Dose of Lenalidomide (Phase I) — 6; 1 number of patients without DLT
Phase 2 N=44 Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Number of Participants With Complete Response (CR) — 14 participants
Phase 3 N=817 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
Leukemia
Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001
Phase 2 N=21 Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)
CLL
Primary: IwCLL-WG Defined Complete Response (CR) — 1 participants
Phase 2 N=26 Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Chronic Lymphocytic Leukemia · Leukemia
Primary: Best Response — 20; 3; 3 Participants
Phase 3 N=391 A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Relapsed or Refractory Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013 — 8.1; NA months — p=<0.0001
Phase 2 N=65 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants
Phase 2 N=91 Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Relapsed or Refractory Chronic Lymphocytic Leukemia · Relapsed or Refractory Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) — 80 Participants — p=<0.0001
Phase 2 N=21 Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
Chronic Lymphocytic Leukemia (CLL)
Primary: Complete Response — 45 Percentage of Participants
Phase 2 N=102 Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Leukemia
Primary: Response Rate — 55.2 percentage
Phase 2 N=64 Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events as a Measure of Safety and Tolerability — 8; 40; 7; 41 participants
Phase 2 N=418 Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: 2-Year Progression Free Survival (PFS) Rate — 0.64; 0.71; 0.74 proportion of participants
Phase 2 N=77 Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) — 15; 30 participants
Phase 2 N=59 Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…
Phase 2 N=51 Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
Leukemia
Primary: Maximum Tolerated Dose (MTD) of Bendamustine Combined With Fixed-Dose Fludarabine and Rituximab (FBR) — 30 mg/m^2
Phase 2 N=21 Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 53 percentage of participants
Phase 2 N=102 Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants
Phase 2 N=35 Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: Rate of Confirmed MRD-negative Response — 0 proportion of patients
Phase 1 N=37 BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=39 Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
Leukemia
Primary: Overall Response Rate — 22; 2; 8; 4 participants
Phase 3 N=652 A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) Assessed by the Investigator — 83.5; 74.2 percentage of participants — p=<0.0001
Phase 2 N=97 A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Documented CR, CRi, or PR at the End of Induction Treatment — 82.4 percentage of participants — p=0.0008
Phase 3 N=160 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression-free Survival (PFS) — NA; 8.38 months — p=<0.0001